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n	 INTRODUCTION
Rheumatoid arthritis (RA) is a chronic systemic disease characterized by an 
inflammatory arthritis, which can lead to 
permanent damage and long-term disabil-
ity. Its treatment has evolved over the years 
with the aim not only of controlling disease 
activity, but also of preventing long-term 
damage and the related disability and mor-
tality (1). To date, many drugs are available 
which have been demonstrated to be effec-
tive in controlling disease activity and re-
ducing radiographic progression and joint 
damage, so that prevention of disability is 
considered an achievable goal.
Among the high number of available treat-
ments, methotrexate (MTX) is considered 
the anchor drug in the treatment of RA due 
to its high efficacy and safety profile as-
sociated with relatively low costs, so that 
international guidelines recommend that it 
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SUMMARY
The study aimed to assess in a population of subjects with rheumatoid arthritis (RA) treated with methotrexate 
(MTX) how the initial approach to the treatment influenced subsequent disability.
We performed a cross-sectional analysis of data collected during the baseline visit of the MARI study, a mul-
ticenter observational study on patients with RA on treatment with MTX for at least 12 months. Subjects who 
fulfilled the Health Assessment Questionnaire (HAQ) were included in the evaluation. For every patient we 
retrospectively evaluated the disease duration, the duration of symptoms before the diagnosis, the time elapsed 
before first MTX treatment, the initial MTX dose, and the concomitant medications in the first six months of 
therapy. Disability was defined as a DI-HAQ score ≥1.
The study population included 1015 subjects. Patients with a DI-HAQ score ≥1 had a longer duration of symp-
toms before diagnosis, a higher delay in treatment initiation, a lower initial dose of MTX and a more frequent 
co-treatment with symptomatic drugs. Disability was found less frequently in subjects treated with other con-
comitant disease modifying anti-rheumatic drugs (DMARDs) but not with biological agents. Logistic regres-
sion analysis identified as significant predictors of disability: older age, female sex, a longer time to complete 
diagnosis, a delay in starting MTX treatment higher than 6 months, and a concomitant treatment with symp-
tomatic drugs, while a combination therapy with other DMARDs was associated with a lower risk of disability.
A late diagnosis and a delay in starting a treatment with MTX are associated with poorer functional outcomes 
in patients with RA.
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should be prescribed as first line therapy in 
patients with RA (2). 
Many studies showed that the earlier the 
treatment, the better the long-term outcome 
of the disease, and international guidelines 
recommend that treatment with MTX 
should be started as soon as the diagnosis 
is made (2). Moreover, recent recommen-
dations suggest that treatment with MTX 
should be started at appropriate dosages to 
achieve the best control of disease activity 
(3). Nevertheless, a recent survey on Ital-
ian patients with RA followed in rheuma-
tology settings - the Methotrexate in the 
therapy of Rheumatoid Arthritis in Italy 
(MARI) study - showed that the approach 
to treatment with MTX in these subjects is 
still suboptimal, with a large proportion of 
patients starting the treatment with a long 
delay from the time of diagnosis and with 
initial dosages below those recommended 
(4, 5).
On this basis, the aim of our study was 
to assess in a large population of subjects 
with RA on MTX treatment how the initial 
approach to the treatment with MTX could 
have influenced subsequent disability.
n	 MATERIALS AND METHODS
The study was performed on data col-
lected during the MARI study, a large 
multicenter observational study involving 
60 rheumatology units across Italy (both 
hospital-based and outpatient clinics), as 
described elsewhere (4, 5). Patients were 
consecutively enrolled between December 
2011 and October 2013, if they fulfilled the 
criteria for RA, as established in the 1987 
classification of the American College of 
Rheumatology (6), and if they had been on 
treatment with MTX for at least 12 months 
prior to the study.
The analyses for the present study were 
performed on data collected during the 
baseline visit, which included the cross-
sectional assessment of disability through 
the Disability Index of the Italian version 
of the Health Assessment Questionnaire 
(DI-HAQ) (7). Only patients who com-
pleted the questionnaire were included in 
the evaluation. 
Among variables collected at baseline, 
we retrospectively evaluated for every pa-
tient the date of diagnosis, the duration of 
symptoms before the diagnosis, the time 
elapsed before first MTX treatment, and 
the initial MTX dose (i.e., the dose taken 
in the first six months) and route of ad-
ministration. We also assessed concomi-
tant medications in the first six months 
of therapy, such as: symptomatic drugs 
[non-steroidal anti-inflammatory drugs 
(NSAIDs), corticosteroids, analgesic 
drugs], other disease modifying anti-rheu-
matic drugs (DMARDs) (leflunomide, 
hydroxy-chloroquine, sulphasalazine, and 
cyclosporine A), and biological therapies. 
The presence of a positive test for either 
the IgM rheumatoid factor (RF >40 U/
mL) or for the anti-citrullinated protein 
antibodies (ACPA >20 U/mL) was also 
recorded.
The objective of our study was to assess 
which patients and disease characteristics 
and which variables related to initial MTX 
treatment were associated with disability in 
our sample of subjects with RA on MTX 
treatment.
The study was approved by the local Medi-
cal Ethics Committees of the participating 
centers and all patients gave their signed 
informed consent.
Statistical analysis
According to previous studies on patients 
with RA (8, 9), disability was defined as 
a DI-HAQ score ≥1. Descriptive data of 
the study population are presented as 
mean (standard deviation, SD) or median 
(interquartile range, IQR) for continuous 
variables according to normality of the 
distribution, and number (percentages) for 
categorical variables. Characteristics of 
patients with and without disability were 
compared using Student’s t-test or Mann-
Whitney test for continuous variables, and 
Pearson’s χ2-test for dichotomous vari-
ables; probability (p) values <0.05 were 
considered statistically significant.  Predic-
tors of disability were assessed through a 
logistic regression analysis. All analyses 
were performed using a SPSS software 
version 17.0 (Chicago, SPSS, Inc.).
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n	 RESULTS
Among the 1336 RA patients under treat-
ment with MTX enrolled in the MARI 
study, 1015 subjects completed the HAQ 
at the baseline visit and therefore were in-
cluded in the analysis for the present study. 
Characteristics of the study population are 
given in Table I. The mean age of the pa-
tients was 60.6 (SD: 12.7) and 820 (80.8%) 
were women, with a median disease dura-
tion of 6 (IQR: 3; 13) years. The median 
duration of symptoms before diagnosis 
was 6 (IQR: 4; 12) months and treatment 
with MTX had started at the time of the 
diagnosis in 185 (18.2%) patients, within 
3-6 months from the diagnosis in 185 
(18.2%) subjects, within 7-12 months in 
167 (16.5%) patients, while 478 (47.1%) 
patients started MTX over 12 months af-
ter the diagnosis. The mean starting dose 
of MTX was 11.4 (SD: 3.3) mg/week 
and 248 (29.2%) of the patients were pre-
scribed with an initial dose between 12.5 
and 15 mg/week, as recommended in the 
last Italian guidelines (3). Only a minority 
of patients were initially treated with MTX 
alone, while 92% of the included subjects 
received a concomitant treatment with 
symptomatic drugs (corticosteroids and/
or NSAIDs and/or analgesic drugs), almost 
35% of patients were treated from the be-
ginning with a concomitant DMARD, and 
19% with a biological agent. About half of 
the study population showed a DI-HAQ 
score ≥1.
The comparison between patients with and 
without disability according to the HAQ 
score is reported in Table II. By comparing 
patients with a DI-HAQ score ≥1 to those 
with a DI-HAQ score <1, we observed a 
higher proportion of female patients among 
those with disability. The duration of symp-
toms before diagnosis was significantly 
higher in patients with disability as well as 
the proportion of subjects who started the 
treatment with MTX more than 6 and 12 
months after the diagnosis (Figure 1). The 
initial dose of MTX was lower in patients 
with a DI-HAQ score ≥1 and they were 
more frequently treated with symptomatic 
drugs in the first 6 months, especially with 
corticosteroids at dosages higher than 10 
mg/die (15.1% versus 7%, p=0.000). A DI-
HAQ score ≥1 was found less frequently 
in subjects treated with other concomitant 
DMARDs in the first 6 months, while no 
difference was found between patients who 
received a concomitant biological agent at 
the beginning of the treatment and subjects 
who did not.  Patients treated with biolog-
ics in the first 6 months had a higher dura-
tion of symptoms before diagnosis [median 
(IQR) time to diagnosis: 9 (4; 18) versus 
6 (4; 12) months; p=0.035] and a higher 
frequency than subjects who started MTX 
treatment more than a year after the diag-
nosis (53.6% versus 45.6%; p=0.043).
Logistic regression analysis (Table III) 
identified as significant predictors of dis-
ability female sex, an older age, a longer 
time to reach diagnosis (OR: 1.017; 95% 
CI: 1.005-1.028) and a delay in starting 
MTX treatment higher than 6 months (OR: 
1.485; 95% CI: 1.069-2.063). Patients 
initially treated with symptomatic drugs 
were more likely to develop disability, 
while a concomitant treatment with other 
DMARDs at the beginning was associated 
Table I - Characteristics of the study population (1015 patients with Rheuma-
toid Arthritis on Methotrexate treatment). Values are given as mean (Standard 
Deviation, SD), median (interquartile range, IQR), or number (percentages).
Age (years); [mean (SD)] 6.6 (12.7)
Sex (female); [n (%)] 820 (80.8%)
Disease duration (years); [median (IQR)] 6 (3; 13)
MTX treatment duration (months); [median (IQR)] 55 (27; 103)
Time to reach diagnosis (months); [median (IQR)] 6 (4; 12)
Time of starting MTX after diagnosis; [n (%)]:
-  at the time of diagnosis
-  3- 6 months after diagnosis
-  7-12 months after the diagnosis
-  >12 months after diagnosis 
185 (18.2%)
185 (18.2%)
167 (16.5%)
478 (47.1%)
Starting dose of MTX (mg/week); [mean (SD)] 11.4 (3.3)
ACPA positivity; [n (%)] 569 (56.1%)
Rheumatoid Factor positivity; [n (%)] 656 (64.6%)
Concomitant medications in the first 6 months; [n (%)]:
-  Symptomatic drugs (NSAIDs, CS, analgesic)
-  Other DMARDs
-  Biologics
932 (91.8%)
354 (34.9%)
194 (19.1%)
MTX: methotrexate; ACPA: anti-citrullinated peptides antibodies; NSAID: non-
steroidal anti-inflammatory drugs; CS: corticosteroids; DMARDs: disease-
modifying anti-rheumatic drugs.
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Table II - Comparison between subjects without disability (DI-HAQ score <1) and with disability (DI-HAQ score ≥1) among 1015 pa-
tients with Rheumatoid Arthritis on Methotrexate treatment. Values are given as mean (Standard Deviation, SD), median (interquartile 
range, IQR) or number (percentages).
DI-HAQ score <1 (n=511) DI-HAQ score ≥1 (n=504) p
Age (years); [mean (SD)] 60.1 (13) 61.2 (12.5) 0.178
Sex (female); [n (%)] 390 (76.3%) 430 (85.3%) 0.000
Disease duration (years); [median (IQR)] 6 (3; 12) 6.5 (3; 13) 0.432
MTX treatment duration (months); [median (IQR)] 57 (30; 100) 52 (25; 110) 0.356
Time to diagnosis (months); [median (IQR)] 6 (3; 12) 8 (5; 12) 0.002
Time to treatment >6 months; [n (%)] 302 (59.3%) 344 (68.5%) 0.002
Time to treatment >12 months; [n (%)] 222 (43.4%) 256 (50.8%) 0.019
Starting dose of MTX (mg/week); [mean (SD)] 11.7 (3.5) 11.2 (3.0) 0.030
ACPA positivity; [n (%)] 289 (56.6%) 280 (55.6%) 0.748
Rheumatoid Factor positivity; [n (%)] 329 (64.4%) 327 (64.9%) 0.868
Concomitant medications in the first 6 months; [n (%)]:
-  Symptomatic drugs (NSAIDS, CS, analgesic)
-  DMARDs
-  Biologics
459 (89.8%)
198 (38.7%)
104 (20.4%)
473 (93.8%)
156 (31%)
90 (17.9%)
0.019
0.009
0.312
MTX: methotrexate; ACPA: anti-citrullinated peptides antibodies; NSAID: non-steroidal anti-inflammatory drugs; CS: corticosteroids; 
DMARDs: disease-modifying anti-rheumatic drugs.
Figure 1 - Proportion of patients with and without disability according to the time of starting 
MTX after the diagnosis.
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with a lower risk of disability (OR: 0.635; 
95% CI: 0.469-0.861).
n	 DISCUSSION
The results of our survey on a wide sam-
ple of subjects with RA on treatment with 
MTX showed that the approach to MTX 
therapy in the early phases of the disease 
could have influenced subsequent disabil-
ity in these patients; an early diagnosis and 
treatment represent the main determinants 
of a good prognosis in patients with RA, 
together with an aggressive approach, as 
suggested by the preventive effect of a con-
comitant administration of other DMARDs 
in the first 6 months of therapy. The main 
strength of our study is the wide represen-
tativeness of our sample, which included a 
high number of patients treated with MTX 
from tertiary care units as well as outpa-
tient services from different geographical 
regions of Italy, with a wide spectrum of 
disease durations. Moreover, direct assess-
ment of patients by rheumatologists may 
provide good reliability of clinical data. 
However, the cross-sectional assessment of 
HAQ score does not provide a longitudinal 
evaluation of disability progression; addi-
tionally, the retrospective collection of data 
regarding initial phases of the disease did 
not allow us to obtain HAQ scores at the 
beginning of treatment, which have been 
demonstrated to be associated with subse-
quent disability (10, 11).
The high proportion of patients with dis-
ability in our study population (about half 
of the patients showed a DI-HAQ score ≥1) 
suggests a suboptimal control of disease 
activity that could be related to the not suf-
ficiently aggressive treatment among Ital-
ian rheumatologists involved in this survey. 
Together with some traditional risk fac-
tors for disability such as female sex and 
older age (8, 11), the results of our study 
confirmed an association between the de-
lay in diagnosis and in starting treatment 
with MTX and higher HAQ scores. These 
findings are in line with current EULAR 
recommendations on the treatment of pa-
tients with RA, which suggest that therapy 
with DMARDs should be started as soon as 
the diagnosis is made (2). Evidence on this 
topic is wide, as many studies showed that 
the earlier the treatment, the better the out-
come for patients with RA:  early diagnosis 
and initiation of treatment are associated 
with decreased disease activity, less joint 
damage progression, and increased func-
tional ability assessed by HAQ (12-14). 
Nevertheless, our survey on a high num-
ber of Italian patients with RA on MTX 
treatment showed that only a minority of 
them started MTX within 6 months from 
the diagnosis (less than 40% of subjects), 
suggesting that many Italian rheumatolo-
gists do not follow the indication of start-
ing MTX as soon as possible (5). 
In the present analysis the starting dose 
of MTX, even if slightly lower in patients 
Table III - Logistic regression analysis for predictors of disability (DI-HAQ score ≥1) among 1015 patients 
with Rheumatoid Arthritis on Methotrexate treatment.
Odds ratio 95% Confidence Interval p
Sex (female) 1.774 1.220 - 2.578 0.003
Age (years) 1.012 1.000 - 1.024 0.043
Disease duration (years) 0.998 0.978 - 1.018 0.813
Time to diagnosis (months) 1.017 1.005 - 1.028 0.004
Time to treatment >6 months 1.485 1.069 - 2.063 0.018
Starting dose of MTX (mg/week) 0.969 0.927 - 1.013 0.162
Concomitant symptomatic drugs 1.843 1.081 - 3.144 0.025
Concomitant DMARDs 0.635 0.498 - 0.861 0.003
Concomitant biologics 0.947 0.661 - 1.356 0.765
MTX: methotrexate; DMARDs: disease-modifying anti-rheumatic drugs.
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with higher DI-HAQ scores, was not sig-
nificantly associated with disability. How-
ever it should be highlighted that the ma-
jority of subjects were initially treated with 
a dose of MTX between 7.5 and 10 mg/
week, while less than 30% of the patients 
received a starting dose of MTX between 
12.5 and 15 mg, as indicated in the latest 
2013 version of the Italian recommenda-
tions (3). Unfortunately, the data collected 
in the present survey did not allow us to 
establish whether an up-titration was done 
in these patients in the early phases of the 
disease.
Another finding emerging from our survey 
is the association between the concomi-
tant administration of symptomatic drugs 
(NSAIDs, corticosteroids and/or analgesic 
drugs) and DI-HAQ scores ≥1. Even if pa-
tients’ disease activity scores at the begin-
ning of the treatment were not available for 
this survey, the use of symptomatic drugs 
could be considered as an indirect sign of 
a more aggressive disease, thus suggest-
ing a higher frequency of disability among 
patients with a more active arthritis when 
starting MTX. This hypothesis could be 
further supported by the finding of a signif-
icant association between the concomitant 
treatment with high dosages of corticoste-
roids in the early phases of the disease and 
the subsequent disability. 
RF and ACPA positivity were not signifi-
cantly associated with DI-HAQ scores in 
our sample. The result concerning RF is 
in line with recent studies, which failed to 
find an association between RF positivity 
and disability progression (9, 15), while 
ACPA positivity significantly influenced 
the probability of developing erosions and 
subsequent disability in most studies. In our 
analysis, however, we considered only ini-
tial treatment, and we cannot exclude that 
patients with ACPA positivity may have 
received a more aggressive treatment in 
the following phases of the disease, which 
could have influenced their functional sta-
tus at the moment of our evaluation.  
Another interesting observation is that con-
comitant treatment with DMARDs other 
than MTX in the first 6 months of therapy 
was associated with a better prognosis of 
patients in terms of disability. This finding 
suggests that a more aggressive approach 
in the early phases of the disease could ob-
tain better long-term results, even if previ-
ous studies on this topic lead to conflicting 
results (2). In a Cochrane meta-analysis, 
which compared MTX monotherapy ver-
sus MTX combination therapy with non-
biologic DMARDs for RA, a significant 
improvement in physical function mea-
sured by HAQ was found in the MTX 
combination group, but only in MTX-inad-
equate responders (16). Conversely, more 
recent data from the CareRA trial did not 
show a different effect of MTX in combi-
nation with other DMARDs compared to 
MTX alone on HAQ scores in patients with 
early RA (17). 
This observation was not replicated, how-
ever, for patients treated with biological 
agents in the first 6 months, who were not 
more likely to have higher HAQ scores. 
Unfortunately, we lack data on DI-HAQ 
and disease activity scores at the beginning 
of treatment, so that we could not assess 
whether patients treated with biologics 
from the beginning had a higher disease 
burden. However, we found that these sub-
jects had a higher delay in diagnosis and 
treatment than those who did not receive 
a biologic agent: this delay could some-
how have counterbalanced the positive 
effect of a more aggressive treatment. It 
may be highlighted, in any case, that less 
than 20% of the study population received 
a combination treatment with biologics in 
the first six months of treatment and less 
than 35% of patients were on therapy with 
a biological agent at the time of our evalu-
ation, despite a median disease duration of 
6 years: this finding further strengthens the 
hypothesis of an insufficiently aggressive 
treatment among Italian rheumatologists 
involved in this survey.
In conclusion, the results of our study 
showed that late diagnosis and delay in 
starting a treatment with MTX are associ-
ated with poorer functional outcomes in 
patients with RA. A more aggressive strat-
egy of treatment in the early phases of the 
disease could ensure better control of sub-
sequent disability in these subjects.
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Conference presentation: paper presented 
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